Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer

Journal of the Pancreas

Volumn 10, Issue 3, 2009, Pages 338-340

  Li, Jia ^a   Peccerillo, Jennifer ^a   Kaley, Kristin ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Erlotinib; Exanthema; Fever; Infection; Pancreatic neoplasms; Sepsis

Indexed keywords

CLINDAMYCIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MINOCYCLINE; OXALIPLATIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CHILL; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; NEUTROPHIL COUNT; PANCREAS CANCER; PRURITUS; RASH; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; WEIGHT REDUCTION; BACTEREMIA; DRUG EFFECT; LETTER; MIDDLE AGED; PANCREAS TUMOR; SKIN; STAPHYLOCOCCUS INFECTION;

BACTEREMIA; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 68149167522     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. National Cancer Institute. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets - Cancer of the Pancreas. http://seer.cancer.gov/statfacts/html/pancreas.html
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
3. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
5. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 1996; 7:133-41.
6. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007; 282:3428-32.
7. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7-14.
8. Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9:59-60.
9. Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23:369-75.
10. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP. J Pancreas (Online) 2008; 9(3):267-74.
11. Santoro F, Cozzani E, Parodi A. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor. J Dermatolog Treat 2006; 17:160-1.
12. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610-21.
13. Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 2008; 19:185-90.
14. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-48.